AstraZeneca Net Profit Margin 2010-2023 | AZN

Current and historical net profit margin for AstraZeneca (AZN) from 2010 to 2023. Net profit margin can be defined as net Income as a portion of total sales revenue. AstraZeneca net profit margin for the three months ending December 31, 2023 was .
AstraZeneca Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2023-12-31 $45.81B $5.96B 13.00%
2023-09-30 $45.00B $5.90B 13.11%
2023-06-30 $44.49B $6.16B 13.85%
2023-03-31 $43.84B $4.71B 10.73%
2022-12-31 $44.35B $3.29B 7.41%
2022-09-30 $45.15B $2.04B 4.52%
2022-06-30 $44.04B $-1.25B -2.85%
2022-03-31 $41.49B $-1.06B -2.56%
2021-12-31 $37.42B $0.11B 0.30%
2021-09-30 $32.82B $1.47B 4.48%
2021-06-30 $29.53B $3.77B 12.77%
2021-03-31 $27.58B $3.98B 14.42%
2020-12-31 $26.62B $3.20B 12.01%
2020-09-30 $25.87B $2.50B 9.65%
2020-06-30 $25.70B $2.15B 8.36%
2020-03-31 $25.25B $1.52B 6.03%
2019-12-31 $24.38B $1.34B 5.47%
2019-09-30 $24.14B $2.06B 8.52%
2019-06-30 $23.07B $2.19B 9.48%
2019-03-31 $22.40B $2.41B 10.75%
2018-12-31 $22.09B $2.16B 9.76%
2018-09-30 $21.45B $2.42B 11.29%
2018-06-30 $22.34B $2.68B 11.98%
2018-03-31 $22.24B $2.80B 12.61%
2017-12-31 $22.47B $3.00B 13.36%
2017-09-30 $22.27B $3.54B 15.90%
2017-06-30 $21.74B $3.87B 17.80%
2017-03-31 $22.29B $3.39B 15.21%
2016-12-31 $23.00B $3.50B 15.21%
2016-09-30 $23.82B $2.47B 10.35%
2016-06-30 $24.06B $2.22B 9.23%
2016-03-31 $24.77B $2.92B 11.79%
2015-12-31 $24.71B $2.83B 11.43%
2015-09-30 $25.03B $1.70B 6.78%
2015-06-30 $25.69B $1.18B 4.59%
2015-03-31 $26.14B $1.28B 4.89%
2014-12-31 $26.55B $1.23B 4.64%
2014-09-30 $26.77B $1.03B 3.85%
2014-06-30 $26.41B $2.02B 7.66%
2014-03-31 $25.88B $2.05B 7.92%
2013-12-31 $25.81B $2.56B 9.90%
2013-09-30 $26.15B $4.59B 17.54%
2013-06-30 $26.58B $4.85B 18.25%
2013-03-31 $27.01B $5.63B 20.83%
2012-12-31 $27.97B $6.24B 22.31%
2012-09-30 $29.35B $6.23B 21.22%
2012-06-30 $30.88B $8.19B 26.53%
2012-03-31 $32.65B $8.71B 26.67%
2011-12-31 $33.59B $9.99B 29.74%
2011-09-30 $33.55B $10.13B 30.19%
2011-06-30 $33.24B $8.21B 24.69%
2011-03-31 $32.99B $8.21B 24.89%
2010-12-31 $33.27B $8.08B 24.28%
2010-09-30 $33.60B $8.01B 23.84%
2010-06-30 $33.90B $8.57B 25.28%
2010-03-31 $33.68B $8.16B 24.23%
2009-12-31 $32.80B $7.53B 22.95%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $238.424B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.812B 105.77
Novo Nordisk (NVO) Denmark $591.861B 45.48
Johnson & Johnson (JNJ) United States $372.169B 14.78
Merck (MRK) United States $332.279B 60.46
AbbVie (ABBV) United States $293.876B 15.18
Novartis AG (NVS) Switzerland $209.653B 14.86
Pfizer (PFE) United States $162.291B 20.17
Sanofi (SNY) $123.116B 11.62
Innoviva (INVA) United States $0.998B 7.01